TABLE 2.
Percent difference in mean 24‐hour TWA between CARDALIS® at the lowest dose (label dose q24h) compared to 2 higher doses (label dose q12h or double label dose q12h).
| Metabolite | CARDALIS® dosage comparison | |
|---|---|---|
| Label dose q12h vs label dose q24h | Double label dose q12h vs label dose q24h | |
| PRA‐S | +32.7% | +129.9% |
| AngI | +36.6% | +147.5% |
| AngII | −2.3% | −30.1% |
| Aldosterone | +63.8% | +116.2% |
| Ang1‐7 | +24.8% | +94.3% |
| Ang1‐5 | −11.8% | −54.1% |
| ACE‐S | −34.0% | −70.7% |
| AA2 | +40.6% | +169.2% |
Note: Positive percent differences indicate that higher dosages of CARDALIS® resulted in higher mean TWA values compared to the label dose q24h, while negative percent differences indicate that higher dosages of CARDALIS® resulted in lower mean TWA values compared to the label dose q24h. Percent differences that were statistically significant (P < .05) in dosage group comparisons are shown in bold. CARDALIS® dosage groups: label dose q24h (benazepril 0.25 mg/kg + spironolactone 2 mg/kg PO q24h); label dose q12h (benazepril 0.25 mg/kg + spironolactone 2 mg/kg PO q12h); and double label dose q12h (0.5 mg/kg benazepril + 4 mg/kg spironolactone PO q12h).
Abbreviations: AA2 ratio, ratio of aldosterone to angiotensin II and measure of adrenal responsiveness to angiotensin II; ACE‐S, surrogate measure of angiotensin‐converting enzyme activity; Ang, angiotensin; PRA‐S, surrogate measure for plasma renin activity.